Thomas Decker

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Cetuximab Versus Folfiri, Oncology, Clinical Trials +9

Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group

Francesco Sardanelli, C. Boetes, Bettina Borisch et al. · European Journal of Cancer · 2010 · 962 citations · Full text

Imaging Anatomy, Breast Oncology, Medical Imaging +8

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 410 citations

Cetuximab Versus Folfiri, Gastrointestinal Oncology, Tumour Dynamics +10

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 377 citations

Advanced Breast Cancer, Breast Oncology, Oncology +11

Comparative genomic hybridization of ductal carcinomain situ of the breast?evidence of multiple genetic pathways

Horst Buerger, Friedrich Otterbach, Ronald Simon et al. · The Journal of Pathology · 1999 · 330 citations